B Cell Lymphoma
B cells are specialized immune cells that are normally activated during an infection. These cells produce antibodies to fight the infection and die when the infection has been eliminated. Genetic changes within B cells can disrupt cellular signaling mechanisms, resulting in cancer.
An enzyme called Bruton’s tyrosine kinase (BTK) is critical in the replication and survival of B cells.
A therapeutic that blocks BTK has the potential to stop B cells from dividing and effectively treat patients suffering from B cell lymphoma.
For more information, please visit:
For detailed information about completed and ongoing clinical studies for Abivertinib (AC0010), ACEA’s dual EGFR/BTK inhibitor, please visit www.clinicaltrials.gov.